Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem; Alberto Gil-Jimenez; Hamza Ali; Jeroen van Dorp; Nick van Dijk; Maurits L. van Montfoort; Maartje Alkemade; Annegien Broeks; Iris M. Seignette; Erik Hooijberg; Wim Brugman; Rhianne Voogd; Bas W.G. van Rhijn; Laura S. Mertens; Jeantine M. de Feijter; Niven Mehra; Antoine G. van der Heijden; Richard P. Meijer; Britt B.M. Suelmann; Wouter Scheper; Lodewyk F.A. Wessels; Daniël J. Vis; Michiel S. van der Heijden

doi:10.1158/1078-0432.30125704

Key Points

T-cell densities at baseline effectively distinguish responders from non-responders in urothelial cancer.
In ipilimumab-high cohorts, responders showed significantly higher T-cell densities than non-responders.
The analysis focused on T-cell subsets in cohorts receiving ipilimumab-high versus ipilimumab-low treatments.
Findings support the potential for T-cell subset analysis in predicting treatment responses in urothelial cancer.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase IB NABUCCO study reveals T-cell subsets differ in responders and non-responders to ipilimumab, indicating treatment efficacy.

Abstract

T-cell subsets at baseline between responders and non-responders for ipilimumab-high and ipilimumab-low. a. T-cell densities at baseline for responders (blue; <=ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3) in the ipilimumab-high cohorts (cohort 1+2A); b. T-cell densities at baseline for responders (blue; <=ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3) in the ipilimumab-low cohort (cohort 2B).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stockem et al. (2025) studied this question.

synapsesocial.com/papers/68d4538731b076d99fa589e8 https://doi.org/10.1158/1078-0432.30125704

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading